GlassScriptPhysician profile
George W Scott, II
NPI 1386845378
$16,608.35
in general payments reported to CMS, 2019-2025
70 companies · $4,276 in 2025
The $4,276 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $523 · 2021: $150 · 2022: $1,609 · 2023: $4,176 · 2024: $5,240 · 2025: $4,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,925.03 |
| Education | $765.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,195.66 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Alexion Pharmaceuticals, INC. | $1,362.08 | 2019-2025 | Ultomiris, Soliris |
| Ucb, INC. | $1,123.26 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Vanda Pharmaceuticals INC. | $635.13 | 2025 | Ponvory |
| Pfizer INC. | $633.04 | 2023-2025 | |
| Eisai INC. | $606.77 | 2019-2025 | |
| Genentech USA, INC. | $564.99 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $547.75 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Csl Behring | $516.90 | 2022-2025 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $513.01 | 2022-2025 | Fycompa |
| Novartis Pharmaceuticals Corporation | $500.21 | 2019-2025 | |
| Argenx US, INC. | $471.54 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $428.53 | 2020-2025 | Vumerity, Tysabri, Plegridy |
| Amgen INC. | $412.36 | 2019-2025 | Uplizna, Aimovig |
| Amneal Pharmaceuticals LLC | $362.76 | 2020-2025 | Rytary, Crexont |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $326.10 | 2019-2025 | Gocovri, Gocovri |
| Banner Life Sciences, LLC | $316.76 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $298.07 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Tg Therapeutics, INC. | $296.11 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $259.36 | 2022 | |
| Emd Serono, INC. | $252.07 | 2023-2025 | Mavenclad |
| Neurelis, INC. | $220.97 | 2023-2025 | Valtoco |
| Sk Life Science, INC. | $218.76 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.34 | 2024-2025 | Hyqvia |
| Alnylam Pharmaceuticals INC. | $190.75 | 2023-2025 | Onpattro |
| Genzyme Corporation | $189.18 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $163.14 | 2020-2025 | Nuplazid |
| Celgene Corporation | $142.26 | 2023-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $141.92 | 2023-2025 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $141.45 | 2020-2024 | Nourianz |
| Sunovion Pharmaceuticals INC. | $138.25 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $137.09 | 2021 | |
| Octapharma USA, INC. | $132.30 | 2023-2025 | Panzyga |
| Janssen Pharmaceuticals, INC | $125.06 | 2019-2024 | Ponvory, Xarelto |
| Livanova USA, INC. | $124.27 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Biotech, INC. | $123.43 | 2025 | |
| Jazz Pharmaceuticals INC. | $120.07 | 2023-2025 | |
| Lundbeck LLC | $106.01 | 2022-2025 | Vyepti |
| Azurity Pharmaceuticals, INC. | $100.43 | 2023-2025 | Horizant, Horizant |
| Impel Pharmaceuticals INC. | $99.89 | 2022-2023 | Trudhesa |
| Grifols USA, LLC | $85.60 | 2024-2025 | Gamunex-C, Xembify |
| Avion Pharmaceuticals | $78.86 | 2022-2023 | Dhivy |
| Abbott Laboratories | $75.46 | 2020-2025 | Infinity |
| Springworks Therapeutics, INC. | $70.59 | 2025 | Gomekli |
| Aprecia Pharmaceuticals, LLC | $62.68 | 2020-2023 | Spritam |
| Ani Pharmaceuticals, INC. | $57.38 | 2023-2025 | Purified Cortrophin Gel |
| Supernus Pharmaceuticals, INC. | $52.52 | 2019-2023 | Oxtellar Xr |
| Boston Scientific Corporation | $48.28 | 2022-2023 | |
| Aucta Pharmaceuticals, INC. | $46.18 | 2025 | Motpoly Xr |
| Vertex Pharmaceuticals Incorporated | $45.59 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $40.56 | 2023-2024 | Andexxa |
| Aquestive Therapeutics, INC. | $38.21 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $37.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $36.60 | 2022 | |
| Allergan, INC. | $36.39 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $36.17 | 2025 | Acthar |
| Merz Pharmaceuticals, LLC | $35.97 | 2025 | Inbrija, Xeomin |
| Otsuka America Pharmaceutical, INC. | $31.08 | 2023-2024 | Nuedexta |
| Sumitomo Pharma America, INC. | $30.89 | 2023-2024 | Aptiom |
| Impel Pharmaceuticals LLC | $30.50 | 2025 | Trudhesa |
| Vertical Pharmaceuticals, LLC | $27.39 | 2019-2020 | |
| Monteris Medical Corporation | $24.18 | 2024 | Neuroblate |
| Genentech, INC. | $23.98 | 2024 | Ocrevus |
| Neuropace, INC. | $19.80 | 2023 | |
| Bio Products Laboratory USA, INC. | $18.57 | 2023 | Gammaplex, Coagadex |
| Merz North America, INC. | $17.40 | 2020 | |
| Scilex Pharmaceuticals INC. | $15.83 | 2023 | Elyxyb |
| Axsome Therapeutics, INC. | $15.09 | 2023 | Sunosi |
| Acorda Therapeutics, INC | $13.41 | 2024 | Inbrija, Ampyra |
| Zyla Life Sciences, INC. | $13.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.